EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sitravatinib enhances doxorubicin cytotoxicity in doxorubicin‐resistant K562 / ADM cells

Min Jeong Ahn, Min Gyo Seo, Eun Hye Kim, Seong Hwan Kim

Bulletin of the Korean Chemical Society · 2026-03 · 47 (3) · 355-360

DOI: 10.1002/bkcs.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin of the Korean Chemical Society, online erschienen am 23.02.2026. Verfasst von Min Jeong Ahn und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Research Institute of Chemical Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance remains a major obstacle in leukemia treatment, and combination therapy has emerged as an effective strategy to overcome this limitation. This study aimed to identify compounds with potent anticancer activity in multidrug‐resistant leukemia cells through a drug repositioning–based screening of clinical‐phase compounds. Among 3120 screened compounds, sitravatinib was identified as a promising hit compound exhibiting significant cytotoxic activity in doxorubicin‐resistant K562/ADM cells. When combined with doxorubicin, sitravatinib showed a synergistic effect, enhancing caspase‐dependent apoptosis and amplifying DNA damage signaling through CHK1 phosphorylation at Ser317. Taken together, this study highlights the therapeutic potential of sitravatinib to be used as a partner drug in doxorubicin combination therapy and provides an effective drug combination strategy for overcoming multidrug resistance in leukemia.

Förderung

  • Korea Research Institute of Chemical Technology

Zitieren

APA

Ahn, M. J., Seo, M. G., Kim, E. H., & Kim, S. H. (2026). Sitravatinib enhances doxorubicin cytotoxicity in doxorubicin‐resistant K562 / ADM cells. Bulletin of the Korean Chemical Society, 47(3), 355-360. https://doi.org/10.1002/bkcs.70117

Vancouver

Ahn MJ, Seo MG, Kim EH, Kim SH. Sitravatinib enhances doxorubicin cytotoxicity in doxorubicin‐resistant K562 / ADM cells. Bulletin of the Korean Chemical Society. 2026;47(3):355-360. doi:10.1002/bkcs.70117

BibTeX
@article{Ahn2026,
  author = {Ahn, Min Jeong and Seo, Min Gyo and Kim, Eun Hye and Kim, Seong Hwan},
  title = {Sitravatinib enhances doxorubicin cytotoxicity in doxorubicin‐resistant K562 / ADM cells},
  journal = {Bulletin of the Korean Chemical Society},
  year = {2026},
  volume = {47},
  number = {3},
  pages = {355--360},
  doi = {10.1002/bkcs.70117}
}
Kostenlos starten →